Fulcrum Therapeutics, Inc. (FULC) has a negative trailing P/E of -6.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 121.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -15.06%, forward earnings yield 0.82%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 62/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -10.0 | 0.00 | 172.99 | 0.00 | - |
| 2018 | -7.0 | -0.17 | 3.01 | 0.00 | - |
| 2019 | -4.6 | -0.06 | 4.33 | 0.00 | - |
| 2020 | -4.2 | 0.19 | 3.12 | 33.65 | - |
| 2021 | -7.7 | 0.44 | 2.96 | 32.64 | - |
| 2022 | -3.0 | -0.51 | 1.65 | 51.65 | - |
| 2023 | -4.3 | 0.13 | 1.76 | 147.54 | - |
| 2024 | -30.0 | 0.33 | 1.20 | 3.64 | - |
| 2025 | -9.6 | -0.02 | 2.05 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-2.10 | $0.00 | $-22.96M | - |
| 2018 | $-1.92 | $0.00 | $-32.59M | - |
| 2019 | $-7.16 | $0.00 | $-79.11M | - |
| 2020 | $-2.70 | $8.82M | $-68.44M | -775.7% |
| 2021 | $-2.22 | $19.16M | $-78.33M | -408.8% |
| 2022 | $-2.35 | $6.34M | $-105.62M | -1665.4% |
| 2023 | $-1.59 | $2.81M | $-97.34M | -3470.1% |
| 2024 | $-0.17 | $80M | $-9.73M | -12.2% |
| 2025 | $-1.18 | $0.00 | $-74.88M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.27 | $-1.69 – $-1.07 | $311.89K | $311.89K – $311.89K | 10 |
| 2027 | $-1.56 | $-2.06 – $-1.23 | $361.24M | $361.24M – $361.24M | 8 |
| 2028 | $-1.09 | $-2.12 – $0.94 | $55.63M | $55.63M – $55.63M | 6 |
| 2029 | $0.07 | $0.07 – $0.07 | $142.9M | $142.9M – $142.9M | 4 |
| 2030 | $1.03 | $1.03 – $1.03 | $234.17M | $234.17M – $234.17M | 2 |
